Capricor Therapeutics Q4 2023 Earnings Report $12.65 -1.05 (-7.66%) As of 04:00 PM Eastern Earnings HistoryForecast Capricor Therapeutics EPS ResultsActual EPS-$0.02Consensus EPS -$0.23Beat/MissBeat by +$0.21One Year Ago EPSN/ACapricor Therapeutics Revenue ResultsActual Revenue$12.09 millionExpected Revenue$5.80 millionBeat/MissBeat by +$6.29 millionYoY Revenue GrowthN/ACapricor Therapeutics Announcement DetailsQuarterQ4 2023Date2/29/2024TimeN/AConference Call ResourcesPress ReleaseCAPR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Capricor Therapeutics Earnings HeadlinesCapricor Therapeutics options imply 7.5% move in share price post-earningsMarch 5 at 7:58 PM | markets.businessinsider.comCapricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD TherapyMarch 5 at 4:33 AM | msn.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.March 5, 2025 | Altimetry (Ad)Capricor Therapeutics stock rises on FDA priority reviewMarch 4 at 6:32 PM | investing.comCapricor Therapeutics' Cell Therapy for Muscular Dystrophy Patients to Get FDA Priority ReviewMarch 4 at 6:32 PM | marketwatch.comCapricor Therapeutics Shares Rise on FDA Priority ReviewMarch 4 at 6:32 PM | marketwatch.comSee More Capricor Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Capricor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capricor Therapeutics and other key companies, straight to your email. Email Address About Capricor TherapeuticsCapricor Therapeutics (NASDAQ:CAPR), Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. View Capricor Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings Broadcom (3/6/2025)Costco Wholesale (3/6/2025)JD.com (3/6/2025)Canadian Natural Resources (3/6/2025)Oracle (3/10/2025)Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
